B7-H1 was originally identified by homology analysis in comparison with B7-1 and B7-2, two molecules with important immunoregulatory functions. B7-H1, however, was broadly induced in the majority of peripheral tissues as well as hematopoietic cells. Upon binding to an as yet unidentified costimulatory receptor on primed T-cells, B7-H1 costimulates T-cell proliferation and preferentially induces interleukin 10 and interferon γ. The costimulatory function of B7-H1 may be critical for enhancing maturation and differentiation of T-cells in lymphoid organs. Conversely, by binding to programmed death 1 receptors on activated T-cells and B-cells, B7-H1 may inhibit ongoing T-cell responses in peripheral tissues by inducing apoptosis and arresting cell-cycle progression. Although a positive regulatory role of B7-H1 has been demonstrated in vitro and in various animal models, a negative regulatory role of B7-H1 has also been documented in human diseases, including cancer, rheumatoid arthritis, and human immunodeficiency virus infection. Delineation of the complex interactions between B7-H1 and its receptors as well as its interplay with other ligands is critical for understanding this new immunoregulatory system. Precise manipulation of B7-H1 and its receptors may provide unique opportunities for designing new disease treatments.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity.Immunol Today. 1993;14:483–486.
Chambers CA, Allison JP. Co-stimulation in T cell responses.Curr Opin Immunol. 1997;9:396–404.
Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen.Annu Rev Immunol. 1993;11:191–212.
Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation.Annu Rev Immunol. 1996;14:233–258.
Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.Immunity. 1995;3:87–98.
Allison JP, Krummel MF. The Yin and Yang of T cell costimulation.Science. 1995;270:932–933.
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med. 1999;5:1365–1369.
Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function.Blood. 2001;97:1809–1816.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J Exp Med. 2000;192:1027–1034.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J. 1992;11:3887–3895.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity. 1999;11:141–151.
Petroff MG, Chen L, Phillips TA, Hunt JS. B7 family molecules: novel immunomodulators at the maternal-fetal interface.Placenta. 2002;23(suppl A):S95-S101.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol. 2001;2:261–268.
Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.J Exp Med. 2001;193:839–846.
Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha.Immunity. 1999;11:423–432.
Yoshinaga SK, Zhang M, Pistillo J, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.Int Immunol. 2000;12:1439–1447.
Wang S, Zhu G, Chapoval AI, et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS.Blood. 2000;96:2808–2813.
Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.Nature. 1999;397:263–266.
Mages HW, Hutloff A, Heuck C, et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand.Eur J Immunol. 2000;30:1040–1047.
Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses.Immunity. 2000;13:95–105.
Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses.Nature. 2001;409:105–109.
Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunode-ficiency.Nat Immunol. 2003;4:261–268.
Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.Nat Immunol. 2001;2:269–274.
Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C. Characterization of mouse and human B7-H3 genes.J Immunol. 2002;168:6294–6297.
Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.J Immunol. 2002;169:3581–3588.
Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function.Nat Immunol. 2001;2:203–209.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med. 2002;8:793–800.
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity.J Mol Med. 2003;81:281–287.
Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.J Immunol. 2003;170:1257–1266.
Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.Immunol Lett. 2002;84:57–62.
Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC.J Immunol. 2002;169:5538–5545.
Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.Nat Med. 2003;9:562–567.
Trabattoni D, Saresella M, Biasin M, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.Blood. 2003;101:2514–2520.
Nishimura H, Agata Y, Kawasaki A, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.Int Immunol. 1996;8:773–780.
Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.Int Immunol. 1996;8:765–772.
Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.Trends Immunol. 2001;22:265–268.
Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.Int Immunol. 1998;10:1563–1572.
Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.Cell. 1992;68:855–867.
Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science. 2001;291:319–322.
Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.Proc Natl Acad Sci U S A. 2001;98:13866–13871.
Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.J Exp Med. 2003;197:1083–1091.
Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes.Nat Immunol. 2002;3:999–1005.
Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy.Nat Immunol. 2001;2:293–299.
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor.Annu Rev Immunol. 2001;19:683–765.
Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression.Immunology. 2001;103:131–136.
Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.J Exp Med. 1994;179:523–532.
Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed withCorynebacterium parvum.Cancer Res. 1994;54:5420–5423.
Stremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism.J Exp Med. 1999;189:919–930.
Maeda A, Yamamoto K, Yamashita K, et al. The expression of costimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia.Br J Haematol. 1998;102:1257–1262.
Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy.Blood. 2000;96:1274–1279.
Salmon M, Gaston JS. The role of T-lymphocytes in rheumatoid arthritis.Br Med Bull. 1995;51:332–345.
Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.J Immunol. 1999;162:4328–4335.
Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis.J Clin Invest. 2003;111:363–370.
About this article
Cite this article
Tamura, H., Ogata, K., Dong, H. et al. Immunology of B7-H1 and Its Roles in Human Diseases. Int J Hematol 78, 321–328 (2003). https://doi.org/10.1007/BF02983556
- Autoimmune diseases